There has been speculation for a likely merger of Generic drugmaker Mylan with Teva Pharmaceuticals. However, Mylan has not given any signal for the same and instead wants to put the speculation to rest. A possible deal would have a hard time winning anti-trust clearances.
Assumption of a Teva bid pushed Mylan shares higher by over 4% on Friday and trading close at a $32 billion market capitalization. Shares of Teva increased more than 2%.